6533b852fe1ef96bd12aac57
RESEARCH PRODUCT
Hydroxychloroquine, COVID ‐19 and diabetes. Why it is a different story
Anca Pantea StoianDoina CatrinoiuManfredi RizzoManfredi RizzoCeriello Antoniosubject
Blood Glucosemedicine.medical_specialty2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)Endocrinology Diabetes and MetabolismSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)MEDLINE030209 endocrinology & metabolismGlycemic Control030204 cardiovascular system & hematologySeverity of Illness IndexDiabetes Complications03 medical and health sciences0302 clinical medicineEndocrinologyCommentariesInternal medicineDiabetes mellitusSeverity of illnessDiabetes MellitusInternal MedicinemedicineHyperglycaemiaHumansHypoglycemic AgentsBlood Glucose COVID-19 Diabetes Complications Diabetes Mellitus Glycemic Control Humans Hydroxychloroquine Hypoglycemic Agents SARS-CoV-2 Severity of Illness Index Signal TransductionSARS-CoV-2business.industryDiabetesCOVID-19Hydroxychloroquinemedicine.diseaseCOVID-19 Drug TreatmentACE2 Cardiovascular disease COVID‐19CommentarybusinessHydroxychloroquineSignal Transductionmedicine.drugdescription
Hydroxychloroquine has been proposed for the cure of the COVID-19 due to its anti-inflammatory and anti-viral action. People with diabetes are more prone to severe outcome if affected by COVID-19 and the use of Hydroxychloroquine might have some benefit in this setting. However, the use of Hydroxychloroquine in diabetes deserves particular attention for its documented hypoglycemic action.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2020-07-20 | Diabetes/Metabolism Research and Reviews |